Kotak fund to invest Rs.1,445-Cr in Matrix Pharma

Kotak Alternate Asset Managers has invested INR 1,445 crore in Hyderabad-headquartered Matrix Pharma through a combination of debt and equity to help the company acquire the active pharmaceutical ingredient (API) business of Pennsylvania (US)-headquartered Viatris . Post-acquisition, Matrix will become the second largest Indian API player with global leadership in antiretroviral (ARV) APIs.Matrix is also expected to gain access to strong research and development capabilities, including over 185 scientists and 600 DMF (drug master file) filings. With regulatory approvals for the US and EU, it will be able to leverage its long-standing relationships with global pharma majors.Viatris was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, in November 2020.